NEO 1940

Drug Profile

NEO 1940

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NEOMED
  • Class Antiemetics; Appetite stimulants; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cachexia

Highest Development Phases

  • Phase I Cachexia; Cancer pain; Nausea and vomiting

Most Recent Events

  • 30 Jan 2018 Artelo Biosciences and NEOMED enter into exclusive global option license agreement for NEO 1940
  • 11 May 2016 Phase I development is ongoing in Canada
  • 30 Apr 2013 Therapeutic efficacy and adverse events data from a phase I trial in Cachexia, Cancer pain, Nausea and vomiting released by NEOMED
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top